Narcolepsy has spent decades as a punchline: someone falls asleep at precisely the wrong moment, or suddenly crumples to the floor. But the reality is neither that simple nor remotely funny. It can mean overwhelming daytime sleepiness, frightening experiences at the boundary between sleep and waking, and a daily struggle to protect a few precious hours of energy.
This article draws on the original reporting and interviews from Science Weekly (The Guardian), which reports that a first-of-its-kind drug targeting the underlying biology of type 1 narcolepsy has received US Food and Drug Administration approval.
The science behind that approach is fascinating. It connects a colony of narcoleptic dogs, experiments originally concerned with appetite, and the discovery of a brain chemical that helps keep us awake. For people living with narcolepsy, its importance is much more personal: the possibility of getting more of their lives back.
What Narcolepsy Actually Feels Like
There are two main forms of narcolepsy, type 1 and type 2. Both involve excessive daytime sleepiness. That does not necessarily mean abruptly falling asleep halfway through a sentence. It can mean feeling intensely sleepy during the day and needing naps that, for many people with narcolepsy, are genuinely refreshing.
Sleep testing can help identify the condition by measuring how quickly someone falls asleep and how quickly they enter rapid eye movement, or REM, sleep. Most people pass through non-REM sleep before reaching this dream-associated stage. People with narcolepsy can enter REM unusually quickly.
Other symptoms can make the distinction between sleeping and waking feel alarmingly uncertain:
- Sleep paralysis: being aware but temporarily unable to move when falling asleep or waking.
- Sleep-related hallucinations: experiences that can seem vividly real at the edges of sleep.
- Intense dreaming: dreams that can be difficult to distinguish from something that actually happened.
The National Institute of Neurological Disorders and Stroke’s narcolepsy overview provides further background on the condition, its symptoms and diagnosis.
When a Dream Feels Like an Intruder
Julie Flygare, who founded the sleep-health nonprofit Project Sleep, was diagnosed with narcolepsy at 24. One experience before her diagnosis stayed with her.
Shortly after graduating from college, she moved into her first adult home. One night, she seemed to wake to the sound of a burglar coming through the living-room window. Her bedroom door opened, and a man rushed towards her with his arms reaching for her neck.
She could not respond. She felt trapped in her own body, convinced she was about to be attacked.
Then the figure disappeared, and she could move again. She checked the living room and found no evidence of a break-in. Nothing had happened, but the experience had not felt like an ordinary dream. It had felt real.
That is a very different picture from the familiar comedy sketch. Narcolepsy can affect not only someone’s ability to stay awake, but their sense of what is happening around them.
Cataplexy Is Not the Same as Falling Asleep
Type 1 narcolepsy also involves a symptom called cataplexy: a sudden loss of muscle tone, often triggered by strong emotion.
Laughter, surprise, shock or anger can bring on an episode. Someone’s knees might buckle, their head might drop, or their whole body might collapse. Crucially, the person remains conscious. Their muscles have weakened; they have not simply fallen asleep.
This distinction explains some of the collapses popularly associated with narcolepsy. What looks from the outside like an abrupt sleep episode may actually be someone fully aware of their surroundings but unable to move.
For Julie, milder episodes can be frustrating. She plays tennis, and sometimes her grip on the racket gives way just as she is about to make a good shot.
Full-body cataplexy is another matter. After collapsing, she mentally urges herself to move a finger or a toe. Her heartbeat and automatic breathing continue, but she describes wanting to take a deeper breath and being unable to do so voluntarily.
In her experience, an episode might pass after about 30 seconds to a minute. That can sound brief on paper. When you are conscious and waiting for your body to respond, it can feel very long indeed.
These experiences have changed how Julie thinks about ordinary movement. Moments without weakness or paralysis are not something she takes for granted.
The Invisible Work of Planning Every Day
Much of narcolepsy’s impact happens out of sight. Excessive sleepiness can restrict work, crowd out hobbies and make everyday activities difficult. Driving raises obvious safety concerns when staying awake is already a struggle, while sudden muscle weakness creates risks of its own.
Julie describes narcolepsy as a factor in every decision she makes. She feels she has roughly four to six particularly good hours in the morning, and she has to allocate them carefully to what matters most.
Later, usually between about 4pm and 6pm, she expects sleepiness to arrive and knows she will need to lie down for at least 30 minutes to an hour. Whether that fits neatly into the day is another question.
She compares the feeling to knowing that an intruder is coming and trying to finish one more thing before they arrive. The uncertainty is not whether sleepiness will interrupt her, but how much she can accomplish beforehand.
That is why a treatment that improves wakefulness could mean much more than feeling a little less tired. It could change the amount of usable time someone has, and the choices available within it.
Existing Treatments Help, but They Have Trade-Offs
Medicines already help manage narcolepsy symptoms. Stimulants can help people stay awake during the day, and some antidepressants can help reduce cataplexy. Other medicines are used too.
But symptom relief can come with side effects. Julie recalls working through treatment options and repeatedly hoping that a better one would turn up.
The appeal of an orexin-targeting treatment is therefore not simply that it is another medicine. It takes a different approach: acting on a signalling system directly implicated in type 1 narcolepsy.
To understand why that matters, we need to go back to the discoveries that revealed what was going wrong.
How Dogs and Mice Revealed the Role of Orexin
In the 1990s, Professor Emmanuel Mignot at Stanford studied a colony of dogs with inherited narcolepsy. By investigating their DNA, he identified a mutation affecting a receptor in the brain.
That receptor responds to orexin, a brain-signalling molecule also known as hypocretin. In those dogs, the receptor was not functioning properly.
At around the same time, another researcher was studying orexin because of its possible role in appetite. Removing orexin from mice produced an unexpected result: the animals developed narcolepsy.
The two findings pointed towards the same system from different directions:
- In the dogs, a faulty receptor prevented the orexin signal from working normally.
- In the mice, removing orexin itself produced narcolepsy.
Together, they made orexin central to understanding the biology of type 1 narcolepsy.
A Conductor for Sleep and Wakefulness
Orexin is a neuropeptide produced by neurons in the hypothalamus. A useful way to think about it is as a conductor helping coordinate sleep and wakefulness.
As we remain awake, pressure to sleep builds. Orexin signalling helps sustain wakefulness despite that increasing pressure, while its activity falls during sleep.
In human type 1 narcolepsy, the problem is generally different from the receptor mutation found in the dogs. The neurons that produce orexin are lost or damaged. Around 90% of these neurons may be affected.
The signalling machinery is therefore missing a crucial input. Understanding that distinction suggests a route to treatment: activate the receptors that would normally receive the orexin signal.
Could Type 1 Narcolepsy Be an Autoimmune Condition?
Many researchers now believe that type 1 narcolepsy has an autoimmune basis. The proposed explanation is that something, perhaps an infection, triggers the immune system to attack orexin-producing neurons.
Once those neurons are destroyed, the brain can no longer produce its normal supply of orexin.
The comparison with type 1 diabetes is helpful. In that condition, the immune system attacks cells that produce insulin. In type 1 narcolepsy, the suspected target is a particular population of brain cells producing a different essential signal.
This remains an area of research. But it reframes the condition: not as a peculiar habit of falling asleep, but as a disorder involving the loss of a specific biological system.
Why an Orexin Agonist Could Be So Important
The new approach uses an orexin agonist. An agonist activates a receptor. In this case, the drug stimulates receptors that normally respond to orexin, mimicking part of the missing signal.
Rather than merely pushing someone to stay awake through a separate mechanism, the aim is to compensate for the signalling deficit at the heart of type 1 narcolepsy.
Science Weekly reports successful trial results and FDA approval for this approach. The discussion does not identify the medicine by name or provide prescribing details, so it should not be treated as a guide to choosing treatment.
The development also gives particular significance to a prediction Mignot made in a 2022 Science Weekly interview: he expected a treatment addressing narcolepsy’s biology within about five years.
Julie took part in the trial. She describes enjoying the wakefulness and feeling that life seemed brighter. She also heard from people who had been able to take up hobbies they previously could not manage.
For the narcolepsy community, news of the development brought a powerful emotional response. Even though Julie knew an announcement was approaching and Project Sleep was preparing information about it, the news still affected her deeply.
Responses came from around the world. Some people had doubted that they would see such a development in their lifetime. A mother in Peru described the hope it offered for her young daughter with narcolepsy.
The significance is both scientific and human: identifying a missing signal, developing a way to activate its receptors, and potentially returning time and opportunity to people whose days have long been constrained.
What Still Needs to Be Answered
Excitement is justified, but there are important questions left.
Side effects occurred during the trial, and there is more to understand about dosage. Regulatory decisions also differ between countries, and an approval announcement does not mean immediate access for everyone.
There is a separate scientific challenge too: type 2 narcolepsy does not have the same established orexin deficiency. Orexin levels are generally normal, and its cause remains unclear.
Some scientists are investigating whether other receptors or signalling processes might be involved in either or both forms. A biological explanation for type 1 should not be assumed to explain type 2.
Nor does activating orexin receptors mean the lost neurons have been restored. The importance of the approach is that it addresses the missing signalling, not that it has been shown to reverse the underlying cell loss.
A Bigger Possibility for Sleep Medicine
Narcolepsy is rare, affecting roughly one in 2,500 people in the estimate discussed by Science Weekly. Sleep problems more broadly are far from rare.
That makes the orexin story interesting beyond this one condition. Scientists and pharmaceutical companies will want to understand how the system contributes to other sleep disorders and where receptor-targeting medicines might help.
Those possibilities remain questions, not promises. But the journey is remarkable: from not knowing the cause of narcolepsy a few decades ago to developing medicines aimed at a specific biological deficit.
For people living with the condition, the most meaningful outcome would be straightforward: more reliable wakefulness, more room for work and hobbies, and less of life organised around the next unavoidable interruption.
Be the first to comment